Rathbones Group PLC Has $10.06 Million Holdings in Edwards Lifesciences Corporation $EW

Rathbones Group PLC lessened its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 79.5% in the second quarter, HoldingsChannel reports. The fund owned 128,616 shares of the medical research company’s stock after selling 499,459 shares during the period. Rathbones Group PLC’s holdings in Edwards Lifesciences were worth $10,059,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently made changes to their positions in EW. Econ Financial Services Corp bought a new position in Edwards Lifesciences during the 2nd quarter worth $889,000. Pacific Capital Partners Ltd bought a new stake in shares of Edwards Lifesciences in the second quarter valued at about $1,760,000. Arkadios Wealth Advisors acquired a new position in shares of Edwards Lifesciences in the second quarter valued at about $300,000. Mirova US LLC increased its position in Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after acquiring an additional 1,054,301 shares during the period. Finally, Czech National Bank raised its stake in Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock worth $11,214,000 after purchasing an additional 7,917 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $83.37 on Monday. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $87.09. The stock has a market capitalization of $48.38 billion, a price-to-earnings ratio of 12.00, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company’s 50 day simple moving average is $77.78 and its 200 day simple moving average is $77.41.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the business posted $0.67 EPS. The company’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on EW. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target on the stock in a research report on Monday, November 3rd. Mizuho lifted their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Finally, Evercore ISI upped their target price on Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.